Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete Pathologic response after Neoadjuvant chemotherapy

被引:82
|
作者
Goldstein, Neal S.
Decker, David
Severson, Dawn
Schell, Scoff
Vicini, Frank
Margolis, Jeffrey
Dekhne, Nayana S.
机构
[1] William Beaumont Hosp, Dept Anat Pathol, Royal Oak, MI 48073 USA
[2] William Beaumont Hosp, Dept Med Oncol, Royal Oak, MI 48072 USA
[3] William Beaumont Hosp, Dept Surg Oncol, Royal Oak, MI 48072 USA
[4] William Beaumont Hosp, Dept Radiat Oncol, Royal Oak, MI 48072 USA
关键词
molecular classification system; invasive breast cancer; complete pathologic response; neoadjuvant chemotherapy; receptor status;
D O I
10.1002/cncr.22981
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The molecular classification system categorizes invasive breast carcinomas according to their key driving biomarkers. In the current study, the authors evaluated whether response to neoadjuvant chemotherapy was correlated with the molecular classification groups. METHODS. Using immunohistochemistry, the molecular classification group (luminal-A, luminal-B, HER-2-variant, HER-2-classic, and basal phenotype) was retrospectively determined in 68 breast cancer patients who received neoadjuvant treatment. RESULTS. A total of 28 carcinoma patients (41.2%) achieved a compete pathologic response (CPR), including 2 of 15 patients classified as having luminal-A (13.3%), 4 of 16 patients classified as having luminal-B (25.0%), 10 of 12 patients classified as having HER-2-classic (83.3%), none of the 4 patients classified as having HER-2-variant, and 12 of 21 patients classified as having basal phenotype (57.1%) neoplasms. The CPR rate among patients with the HER-2-classic and basal neoplasms was 67% (22 of 33 neoplasms), compared with 17.1% (6 of 35 neoplasms) in the non-HER-2-classic/basal combined group (P < .001). Eleven carcinomas were initially diagnosed as invasive lobular carcinomas (pleomorphic and classic), 4 of which were luminal-A, 4 of which were luminal-B, 2 of which were HER-2-classic, and 1 of which was basal. On review, only 3 of these 11 cases remained classified as classic lobular carcinoma,;01 of which were classified as luminal-A, and none of these patients achieved a CPR. Four of the other 8 patients achieved a CPR. CONCLUSIONS. The molecular classification system is useful for identifying carcinoma patients who are most likely and those who are least likely to achieve a CPR. In the current study, all the morphologically classic lobular carcinomas were classified as luminal-A neoplasms, which may explain the low rate of CPR reported.
引用
收藏
页码:1687 / 1696
页数:10
相关论文
共 50 条
  • [31] Prognostic factors for patients with invasive ductal carcinoma of the breast who received neoadjuvant chemotherapy
    Tamura, N.
    BREAST, 2009, 18 : S33 - S33
  • [32] Prognostic factors for patients with invasive ductal carcinoma of the breast who received neoadjuvant chemotherapy
    Tamura, N.
    Tamura, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
    M Tanioka
    C Shimizu
    K Yonemori
    K Yoshimura
    K Tamura
    T Kouno
    M Ando
    N Katsumata
    H Tsuda
    T Kinoshita
    Y Fujiwara
    British Journal of Cancer, 2010, 103 : 297 - 302
  • [34] Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
    Tanioka, M.
    Shimizu, C.
    Yonemori, K.
    Yoshimura, K.
    Tamura, K.
    Kouno, T.
    Ando, M.
    Katsumata, N.
    Tsuda, H.
    Kinoshita, T.
    Fujiwara, Y.
    BRITISH JOURNAL OF CANCER, 2010, 103 (03) : 297 - 302
  • [35] Pathologic Complete Response Rate and Clinical Outcome of Metaplastic Breast Carcinoma After Neoadjuvant Chemotherapy
    Han, Min
    Zhang, Huina
    Clark, Beth
    Dabbs, David
    Bhargava, Rohit
    MODERN PATHOLOGY, 2018, 31 : 67 - 68
  • [36] Pathologic Complete Response Rate and Clinical Outcome of Metaplastic Breast Carcinoma After Neoadjuvant Chemotherapy
    Han, Min
    Zhang, Huina
    Clark, Beth
    Dabbs, David
    Bhargava, Rohit
    LABORATORY INVESTIGATION, 2018, 98 : 67 - 68
  • [37] A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy
    Alan, Ozkan
    Telli, Tugba Akin
    Ercelep, Ozlem
    Hasanov, Rahib
    Simsek, Eda Tanrikulu
    Mutis, Aydan
    Ones, Tunc
    Kaya, Handan
    Yumuk, Perran Fulden
    CURRENT PROBLEMS IN CANCER, 2019, 43 (04) : 308 - 311
  • [38] The molecular classification system is useful for determining the likelihood of complete pathologic response to neoadjuvant chemotherapy in locally advance breast cancer
    Young, M.
    Goldstein, N. S.
    MODERN PATHOLOGY, 2007, 20 : 55A - 55A
  • [39] Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype
    Ko, Eun Sook
    Han, Heon
    Han, Boo-Kyung
    Kim, Sun Mi
    Kim, Rock Bum
    Lee, Gyeong-Won
    Park, Yeon Hee
    Nam, Seok Jin
    KOREAN JOURNAL OF RADIOLOGY, 2015, 16 (05) : 986 - 995
  • [40] The molecular classification system is useful for determining the likelihood of complete pathologic response to neoadjuvant chemotherapy in locally advance breast cancer
    Young, M.
    Goldstein, N. S.
    LABORATORY INVESTIGATION, 2007, 87 : 55A - 55A